Vivos Therapeutics Raises $4.64 Million Through Warrant Exercise
ByAinvest
Friday, Jan 16, 2026 8:02 am ET1min read
VVOS--
Vivos Therapeutics has announced the exercise of warrants for $4.64 million gross proceeds, with H.C. Wainwright & Co. as the exclusive placement agent. The company will issue new unregistered warrants to purchase up to 3,964,712 shares of common stock at an exercise price of $2.09 per share. The net proceeds will be used for working capital and general corporate purposes. The offering is expected to close on January 20, 2026, subject to customary closing conditions.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet